DHA‐enriched phosphatidylserine ameliorates high‐fat diet‐induced kidney injury in mice possibly by regulating TLR4/NF‐κB and AMPK pathways
Authors:
- 20 August 2022
- journal article
- research article
- Published by Wiley in Journal of Food Science
- Vol. 87 (9) , 4233-4249
Abstract
The present study sought to investigate the amelioration effects of enzymatically synthesized docosahexaenoic acid‐enriched phosphatidylserine (DHA‐PS) on the high‐fat diet (HFD)‐induced kidney injury in mice. After 6 weeks of DHA‐PS intervention, the mice's body weight in the 20 and 40 mg/kg DHA‐PS groups decreased by 7.09% and 9.71%, respectively, compared to the HFD group. Especially, compared to the HFD group, 40 mg/kg DHA‐PS treatment effectively reduced the levels of serum urea nitrogen by 68.48%, creatinine by 38.98%, kidney lipid accumulation (total cholesterol, triglycerides, and nonesterified fatty acids levels by 26.19%, 51.00%, and 26.11%), kidney or serum proinflammatory cytokines and enhanced the levels of kidney or serum oxidative stress parameters, except for malondialdehyde (MDA). Moreover, 40 mg/kg DHA‐PS treatment decreased the expression levels of toll‐like receptor 4 (TLR4) by 18.63%, IKKα by 31.81%, and p‐p65 by 40.73% in the nuclear factor kappa‐B pathway, thereby upregulating the expression levels of p‐AMPKα by 64.93%, HSL by 99.60%, ATGL by 344.50%, PPARα by 162.02%, CPT1 by 167.95%, p‐ACC1 by 144.92%, and p‐SREBP1 by 1172.95%, and downregulating the expression levels of SREBP1 by 38.80%, ACC1 by 18.10%, and FAS by 82.28% in the AMPK pathway. Furthermore, our results also suggested that improving serum or kidney parameters and regulating intestinal microbial could affect each other after DHA‐PS treatment. These results elucidated that DHA‐PS could be a potential dietary supplement to alleviate HFD‐induced kidney injury. Practical Application: Our results elucidated that DHA‐PS could be a potential dietary supplement to alleviate HFD‐induced kidney injuryKeywords
Funding Information
- Zhejiang Provincial Xinmiao Talents Program (No.2021R411034)
This publication has 56 references indexed in Scilit:
- Fatty kidney: emerging role of ectopic lipid in obesity-related renal diseaseThe Lancet Diabetes & Endocrinology, 2014
- Obesity Paradox in End-Stage Kidney Disease PatientsProgress in Cardiovascular Diseases, 2014
- Fibrates: Therapeutic potential for diabetic nephropathy?European Journal of Internal Medicine, 2012
- AMPK Mediates the Initiation of Kidney Disease Induced by a High-Fat DietJournal of the American Society of Nephrology, 2011
- Phosphatidylserine-containing liposomes suppress inflammatory bone loss by ameliorating the cytokine imbalance provoked by infiltrated macrophagesLaboratory Investigation, 2011
- High-fat and low-carbohydrate diet feeding down-regulates the expression of the AMP-activated protein kinase pathway in rat cardiac muscleProcess Biochemistry, 2010
- Apoptotic mimicry: phosphatidylserine liposomes reduce inflammation through activation of peroxisome proliferator‐activated receptors (PPARs) in vivoBritish Journal of Pharmacology, 2007
- Phosphatidylserine and phosphatidylcholine-containing liposomes inhibit amyloid β and interferon-γ-induced microglial activationFree Radical Biology and Medicine, 2007
- Involvement of ERK, a MAP kinase, in the production of TGF-β by macrophages treated with liposomes composed of phosphatidylserineBiochemical and Biophysical Research Communications, 2004
- Lipase‐Assisted Concentration of n‐3 Polyunsaturated Fatty Acids from Viscera of Farmed Atlantic Salmon ( Salmo salar L.)Journal of Food Science, 2002